Skyhawk deal with Celgene confirms growing importance of platform technologies in life sciences IP value creation
Increased focus on gene and cell-related therapies as well as falling R&D returns, promise to heighten biopharma interest in tapping into the potential of SkySTAR and other platforms
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.